Concentrations of glial fibrillary acidic protein in the blood serum of patients with glioblastoma of the brain

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Glioblastoma is one of the most aggressive malignant brain tumors. In a number of observations, these tumors are not sensitive to drug therapy, are often prone to recurrence, and the prognosis for most patients remains unfavorable. Therefore, one of the promising directions is the search for biomarkers for timely diagnosis and monitoring of the disease.

Aim. To analyze the content of the soluble form of the GFAP protein in the blood serum of patients with glioblastoma and determine its prognostic significance.

Material and methods. We examined 178 patients (99 men and 79 women) with glioblastoma of the brain aged from 18 to 82 years, who underwent examination and treatment at the Federal State Budgetary Institution "National Medical Research Center of Oncology named after. N.N. Blokhin" in the period from 2016 to 2023. All of them were diagnosed with glioblastoma (IV degree of malignancy), which was confirmed by morphological and molecular genetic studies. The control group consisted of 34 healthy donors (18 men and 16 women) aged from 19 to 80 years and the comparison group of 31 patients (26 men and 5 women) with traumatic brain injuries of varying severity aged 19 to 56 years. GFAP concentrations were determined in blood serum samples from patients with glioblastoma before treatment, and in patients with traumatic brain injuries 2-3 hours after injury using enzyme immunoassay "Human test system GFAP ELISA" (Biovendor, Czech Republic). Data were processed using Statistica 10 (StatSoft) and SPSS (IBM) software. When comparing indicators and analyzing their relationships, the nonparametric Kruskal–Wallis test was used. Analysis of the information content of the diagnostic method by assessing its sensitivity and specificity was carried out by constructing ROC curves and calculating the area under them (AUC). Overall survival analysis was performed using the Kaplan–Meier method. Comparison of the statistical significance of differences between indicators was carried out using the log-rank test. Differences and correlations were considered statistically significant at p < 0.05.

Results. In the blood serum of healthy donors, GFAP was detected only in 8.8% (3 out of 34) of those examined, and its median content was 0 ng/ml. In patients with glioblastoma, GFAP was detected in 73.6% of cases (131 out of 178 patients) and its median content was 0.196 ng/ml. Slightly less frequently (in 20 of 31 patients, 64.5%), GFAP was found in patients with traumatic brain injuries and its median content was 0.027 ng/ml. ROC analysis showed that for the group of patients with glioblastoma, the area under the ROC curve was 0.855 (p = 0.0001), for patients with traumatic brain injury – 0.793 (p < 0.0001). The analysis showed that high levels of GFAP more than 0.014 ng/ml in the blood serum of patients with glioblastoma are prognostically unfavorable, although they did not reach statistical significance (p = 0.4). The median survival of patients was 26.6 months with GFAP levels < 0.014 ng/ml, while in patients with higher levels of this protein (≥0.014 ng/ml) the median survival was 14 months.

Conclusions. GFAP was detected in the blood serum of 73.6% of patients with glioblastoma of the brain, 64.5% of patients with traumatic brain injury, and only 8.8% of healthy donors. GFAP concentrations in patients with glioblastoma and patients with traumatic brain injury did not differ from each other, but were significantly higher compared to the control group. GFAP levels in the blood serum of patients with glioblastoma ≥ 0.014 ng/ml are associated with an unfavorable prognosis of overall survival.

Full Text

Restricted Access

About the authors

O. N. Kleimenova

Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia

Author for correspondence.
Email: olga_kleimnova@mail.ru
ORCID iD: 0009-0008-0869-8067

Post-graduate Student, Department of Clinical Biochemistry and Laboratory Diagnostics

Russian Federation, Dolgorukovskaya St., 4, Moscow, 127006

A. A. Alferov

Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia

Email: aleksandr.alferov@yahoo.com
ORCID iD: 0000-0003-3585-5693

Ph.D. (Med.). Assistant, Department of Clinical Biochemistry and Laboratory Diagnostics

Russian Federation, Dolgorukovskaya St., 4, Moscow, 127006

O. V. Kovaleva

FGBU N.N. Blokhin National Medical Research Center for Oncology

Email: ovkovaleva@gmail.com
ORCID iD: 0000-0001-6132-9924

Dr.Sc. (Biol.), Senior Research Scientist, Laboratory of Regulation of Viral and Cellular Oncogenes

Russian Federation, Kashirskoe shosse 24, Moscow, 115522

N. V. Lyubimova

Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia; FGBU N.N. Blokhin National Medical Research Center for Oncology

Email: ovkovaleva@gmail.com

Dr.Sc. (Biol.), Professor, Department of Clinical Biochemistry and Laboratory Diagnostics, Scientific Consultant, Clinical Diagnostic Laboratory

Russian Federation, Dolgorukovskaya St., 4, Moscow, 127006; Kashirskoe shosse 24, Moscow, 115522

A. A. Mitrofanov

FGBU N.N. Blokhin National Medical Research Center for Oncology

Email: mitrofanov-aa@list.ru
ORCID iD: 0000-0002-4125-7342

Ph.D. (Med.), Research Scientist, Department of Neuro-Oncology

Russian Federation, Kashirskoe shosse 24, Moscow, 115522

A. Kh. Bekyashev

FGBU N.N. Blokhin National Medical Research Center for Oncology

Email: abekyashev@gmail.com
ORCID iD: 0000-0002-4160-9598

Dr.Sc. (Med.), Head of the Department of Neuro-Oncology

Russian Federation, Kashirskoe shosse 24, Moscow, 115522

N. E. Kushlinskii

Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia; FGBU N.N. Blokhin National Medical Research Center for Oncology

Email: kne3108@gmail.com
ORCID iD: 0000-0002-3898-4127

Dr.Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Clinical Biochemistry and Laboratory Diagnostics, Scientific Director of the Clinical Diagnostic Laboratory

Russian Federation, Dolgorukovskaya St., 4, Moscow, 127006; Kashirskoe shosse 24, Moscow, 115522

References

  1. Vaz-Salgado M.A., Villamayor M., Albarrán V., et al. Recurrent Glioblastoma: A Review of the Treatment Options. Cancers (Basel). 2023; 15(17): 4279. doi: 10.3390/cancers15174279.
  2. Brown N.F., Ottaviani D., Tazare J., et al. Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers (Basel). 2022; 14(13): 3161. doi: 10.3390/cancers14133161.
  3. Jung C.S., Foerch C., Schänzer A., et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007; 130 (Pt 12): 3336-41. doi: 10.1093/brain/awm263.
  4. Abdelhak A., Foschi M., Abu-Rumeileh S., et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 2022; 18(3): 158–172. doi: 10.1038/s41582-021-00616-3.
  5. Goyal R., Mathur S.K., Gupta S., et al. Immunohistochemical expression of glial fibrillary acidic protein and CAM5.2 in glial tumors and their role in differentiating glial tumors from metastatic tumors of central nervous system. J. Neurosci. Rural. Pract. 2015; 6(4): 499–503. doi: 10.4103/0976-3147.
  6. van Asperen J.V., Fedorushkova D.M., Robe P.A.J.T., Hol E.M. Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomarkers. 2021; 27(1): 1–12. doi: 10.1080/1354750X.2021.2006313.
  7. Abdelhak A., Huss A., Kassubek J. Tumani H. Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci. Rep. 2018; 8(1): 14798. doi: 10.1038/s41598-018-33158-8.
  8. Tichy J., Spechtmeyer S., Mittelbronn M., et al. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol. 2016; 126(2): 361–369. doi: 10.1007/s11060-015-1978-8.
  9. Lyubimova N.V., Timofeev Y.S., Mitrofanov A.A., et al. Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial Tumors. Bull. Exp. Biol. Med. 2020; 168(4): 503–506. doi: 10.1007/s10517-020-04741-9.
  10. Gullotta F., Schindler F., Schmutzler R., Weeks-Seifert A. GFAP in brain tumor diagnosis: possibilities and limitations. Pathol. Res. Pract. 1985; 180(1): 54–60. doi: 10.1016/S0344-0338(85)80075-3.
  11. Müller Bark J., Kulasinghe A., Chua B., et al. Circulating biomarkers in patients with glioblastoma. Br. J. Cancer. 2020; 122(3): 295–305. doi: 10.1038/S41416-019-0603-6.
  12. Abu-Rumeileh S., Barba L., Bache M., et al. Plasma β-synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy. Ann. Clin. Transl. Neurol. 2023; 10(10): 1924–1930. doi: 10.1002/acn3.51878.
  13. Ahmadipour Y., Gembruch O., Pierscianek D., et al. Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival? Neurochirurgie. 2020; 66(3): 150–154. doi: 10.1016/j.neuchi.2019.12.012.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. ROC analysis of patients with glioblastoma (A) and traumatic brain injury (B)

Download (67KB)
3. Fig. 2. Prognostic significance of serum GFAP levels in patients with glioblastoma

Download (122KB)

Copyright (c) 2024 Russkiy Vrach Publishing House